Grade Iii Astrocytoma malady

Rare diseases, Neuronal diseases, Cancer diseases categories

Aliases & Classifications for Grade Iii Astrocytoma

About this section
8Disease Ontology, 42NIH Rare Diseases, 44Novoseek, 48Orphanet, 61UMLS, 39NCIt, 33MeSH, 56SNOMED-CT, 62UMLS via Orphanet
See all sources

Aliases & Descriptions for Grade Iii Astrocytoma:

Name: Grade Iii Astrocytoma 8 42
Anaplastic Astrocytoma 8 42 44 48 61
Astrocytoma 42 61
Gliosarcoma 42 61
High Grade Astrocytic Tumor 61
Grade Iii Astrocytic Tumor 8
High-Grade Astrocytoma 42
Malignant Astrocytoma 42
Astrocytic Tumor 42


Characteristics (Orphanet epidemiological data):

anaplastic astrocytoma:
Inheritance: Not applicable; Age of onset: Adult

External Ids:

Disease Ontology8 DOID:3078
NCIt39 C9477
MeSH33 D001254
SNOMED-CT56 55353007
Orphanet48 251589
UMLS via Orphanet62 C0334579

Summaries for Grade Iii Astrocytoma

About this section
NIH Rare Diseases:42 Anaplastic astrocytoma is a rare, cancerous (malignant) type of brain tumor that arises from star-shaped brain cells called astrocytes. these cells surround and protect nerve cells in the brain and spinal cord. an anaplastic astrocytoma usually develops slowly over time, but may develop rapidly. signs and symptoms vary depending on the location and size of the tumor and may include headaches, drowsiness, vomiting, and changes in personality or mental status. some affected people have seizures, vision problems, weakness of the limbs, and/or coordination problems. anaplastic astroctyomas usually occur sporadically but can be associated with a few rare, genetic disorders. treatment may include surgery, radiation, and/or chemotherapy. last updated: 11/3/2014

MalaCards based summary: Grade Iii Astrocytoma, also known as anaplastic astrocytoma, is related to renal cell carcinoma and astrocytoma. An important gene associated with Grade Iii Astrocytoma is IDH2 (isocitrate dehydrogenase 2 (NADP+), mitochondrial), and among its related pathways are Integrated Pancreatic Cancer Pathway and Chks in Checkpoint Regulation. The drugs cisplatin and cisplatin pwdr and the compounds 8-oxo-dg and olomoucine have been mentioned in the context of this disorder. Affiliated tissues include brain and spinal cord.

Disease Ontology:8 An astrocytoma that is characterized by cells with regular, round to oval nuclei.

Related Diseases for Grade Iii Astrocytoma

About this section

Diseases related to Grade Iii Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 263)
idRelated DiseaseScoreTop Affiliating Genes
1renal cell carcinoma30.8TP53
2astrocytoma30.7TP53, PCNA
3malignant glioma30.2IDH2, TP53, PCNA
4colorectal cancer30.0PCNA, TP53
5glioblastoma30.0PCNA, TP53, IDH2
6oligodendroglioma30.0TP53, PCNA
7retinoblastoma29.9PCNA, TP53
8breast cancer29.8TP53, PCNA
9papilloma29.8PCNA, TP53
11subependymal giant cell astrocytoma10.9
12cerebellar astrocytoma10.8
13tuberous sclerosis10.8
14pilomyxoid astrocytoma10.7
15juvenile pilocytic astrocytoma10.7
16spinal cord astrocytoma10.7
18gemistocytic astrocytoma10.5
19desmoplastic infantile astrocytoma10.4
21melanoma and neural system tumor syndrome10.4
22glioblastoma multiforme10.4
23protoplasmic astrocytoma10.4
24childhood cerebral astrocytoma10.3
25adult brainstem gliosarcoma10.3
26myelodysplastic syndrome10.3
31diencephalic syndrome10.3
32juvenile astrocytoma10.2
33diencephalic astrocytomas10.2
34pilocytic astrocytoma of cerebellum10.2
35childhood pilocytic astrocytoma10.2
36optic nerve astrocytoma10.2
40meningioma, familial10.2PCNA
42herpes simplex10.2
43dysembryoplastic neuroepithelial tumor10.2
44childhood optic tract astrocytoma10.2
45mixed oligodendroglioma-astrocytoma10.2
48mixed astrocytoma-ependymoma10.1
49mixed astrocytoma-ependymoma-oligodendroglioma10.1
50childhood brainstem astrocytoma10.1

Graphical network of the top 20 diseases related to Grade Iii Astrocytoma:

Diseases related to grade iii astrocytoma

Symptoms for Grade Iii Astrocytoma

About this section

Drugs & Therapeutics for Grade Iii Astrocytoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
Afinitor13 38 EVEROLIMUS Novartis Approved March 2009
FDA Label: Afinitor
Malady that Drug Treats: renal cell carcinoma/ renal angiomyolipoma associated with tuberous sclerosis complex/ advanced pancreatic neuroendocrine tumor
Indications and Usage:13 AFINITOR is a kinase inhibitor indicated for the treatment of: postmenopausal women with advanced hormone receptor-positive, HER2- negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole. (1.1) adults with progressive neuroendocrine tumors of pancreatic origin (PNET) that are unresectable, locally advanced or metastatic. AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors. (1.2) adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. (1.3) adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of AFINITOR in the treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes. (1.4) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of: pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. The effectiveness is based on demonstration of durable objective response, as evidenced by reduction in SEGA tumor volume. Improvement in diseaserelated symptoms and overall survival in patients with SEGA and TSC has not been demonstrated. (1.5)
DrugBank Targets:11 Serine/threonine-protein kinase mTOR
Mechanism of Action:13 
Target: mTOR
Action: inhibitor
FDA: Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the; PI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellular; protein, FKBP-12, resulting in an inhibitory complex formation with mTOR complex 1 (mTORC1) and thus inhibition of; mTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic initiation; factor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. S6K1 is a substrate of; mTORC1 and phosphorylates the activation domain 1 of the estrogen receptor which results in ligand-independent; activation of the receptor. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) and; reduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shown; to reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.; Constitutive activation of the PI3K/Akt/mTOR pathway can contribute to endocrine resistance in breast cancer. In vitro; studies show that estrogen-dependent and HER2+ breast cancer cells are sensitive to the inhibitory effects of everolimus,; and that combination treatment with everolimus and Akt, HER2, or aromatase inhibitors enhances the anti-tumor activity; of everolimus in a synergistic manner.; Two regulators of mTORC1 signaling are the oncogene suppressors tuberin-sclerosis complexes 1 and 2 (TSC1, TSC2).; Loss or inactivation of either TSC1 or TSC2 leads to activation of downstream signaling. In TSC, a genetic disorder,; inactivating mutations in either the TSC1 or the TSC2 gene lead to hamartoma formation throughout the body.
Temodar13 38 TEMOZOLOMIDE Schering-Plough Approved August 1999
FDA Label: Temodar
Malady that Drug Treats: refractory anaplastic astrocytoma
Indications and Usage:13 TEMODAR is an alkylating drug indicated for the treatment of adult; patients with:; Newly diagnosed glioblastoma multiforme (GBM) concomitantly; with radiotherapy and then as maintenance treatment. (1.1); Refractory anaplastic astrocytoma patients who have experienced; disease progression on a drug regimen containing nitrosourea; and procarbazine. (1.2)
DrugBank Targets:11 1. DNA
Mechanism of Action:13 
Target: DNA
Action: alkylizer
FDA: Temozolomide is not directly active but undergoes rapid nonenzymatic conversion at physiologic pH to the reactive compound; 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC). The cytotoxicity of MTIC is thought to be primarily due to alkylation of; DNA. Alkylation (methylation) occurs mainly at the O6 and N7 positions of guanine. ;

Drug clinical trials:

Search ClinicalTrials for Grade Iii Astrocytoma

Search NIH Clinical Center for Grade Iii Astrocytoma

Inferred drug relations via UMLS61/NDF-RT40:

Genetic Tests for Grade Iii Astrocytoma

About this section

Anatomical Context for Grade Iii Astrocytoma

About this section

MalaCards organs/tissues related to Grade Iii Astrocytoma:

Brain, Spinal cord

Animal Models for Grade Iii Astrocytoma or affiliated genes

About this section

Publications for Grade Iii Astrocytoma

About this section

Articles related to Grade Iii Astrocytoma:

Prolonged survival associated with the use of intraoperative carmustine (Gliadel) in a paediatric patient with recurrent Grade III astrocytoma. (23391098)
Proliferating cell nuclear antigen, p53 and micro vessel density: Grade II vs. Grade III astrocytoma. (20090216)
Regression of grade III astrocytoma during the treatment of CML with imatinib mesylate. (16988542)
Mdr1 mRNA expression differs between grade III astrocytomas and glioblastomas. (9020393)
Ukrain therapy in a frontal anaplastic grade III astrocytoma (case report). (8899347)
p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. (1349850)

Variations for Grade Iii Astrocytoma

About this section

Expression for genes affiliated with Grade Iii Astrocytoma

About this section
Search GEO for disease gene expression data for Grade Iii Astrocytoma.

Pathways for genes affiliated with Grade Iii Astrocytoma

About this section

Pathways related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

(show all 17)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.1TP53, PCNA
Show member pathways
9.1PCNA, TP53
Show member pathways
9.1PCNA, TP53
Show member pathways
9.1PCNA, TP53
Show member pathways
Toll-like receptor signaling pathway36
Regulation of toll-like receptor signaling pathway36
9.1PCNA, TP53
69.1PCNA, TP53
Show member pathways
9.1PCNA, TP53
Show member pathways
Cell cycle36
9.1PCNA, TP53
99.1TP53, PCNA
109.1PCNA, TP53
119.1PCNA, TP53
129.1PCNA, TP53
139.1TP53, PCNA
149.1PCNA, TP53
Show member pathways
Signal transduction PTEN pathway59
9.1PCNA, TP53
Show member pathways
Development IGF RI signaling
Immune response IL 4 signaling pathway59
Signal transduction AKT signaling59
9.1PCNA, TP53
179.1PCNA, TP53

Compounds for genes affiliated with Grade Iii Astrocytoma

About this section

Compounds related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

(show all 32)
idCompoundScoreTop Affiliating Genes
18-oxo-dg449.5PCNA, TP53
2olomoucine44 1110.5TP53, PCNA
3temozolomide44 1110.5TP53, PCNA
4sulindac sulfide449.5PCNA, TP53
5o6-methylguanine449.5PCNA, TP53
6aphidicolin449.5TP53, PCNA
7sulindac44 1110.5TP53, PCNA
8dutp449.5PCNA, TP53
9methylmethanesulfonate449.5PCNA, TP53
102-methoxyestradiol44 60 2411.5PCNA, TP53
11roscovitine449.5TP53, PCNA
12adpribose449.5TP53, PCNA
13hydroxyurea44 50 1111.5TP53, PCNA
14gemcitabine44 50 1111.5TP53, PCNA
15mitomycin c449.5TP53, PCNA
16thymidylate449.4PCNA, TP53
17cytarabine44 50 1111.4TP53, PCNA
18resveratrol44 60 24 1112.4PCNA, TP53
19caffeine44 28 1 50 24 1114.4PCNA, TP53
20camptothecin44 60 1111.4TP53, PCNA
21egcg449.4PCNA, TP53
22mg 13244 6010.4PCNA, TP53
23cyclophosphamide44 50 1111.4TP53, PCNA
245-aza-2deoxycytidine449.3PCNA, TP53
25arsenite44 2410.3PCNA, TP53
265fluorouracil449.3PCNA, TP53
27etoposide44 50 60 1112.2PCNA, TP53
28n acetylcysteine449.2TP53, PCNA
29butyrate449.1PCNA, TP53
30paraffin449.1PCNA, TP53
31tamoxifen44 50 28 1112.0PCNA, TP53
32paclitaxel44 50 1110.8TP53, PCNA

GO Terms for genes affiliated with Grade Iii Astrocytoma

About this section

Cellular components related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1mitochondrial matrixGO:00057599.0TP53, IDH2

Biological processes related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cell proliferationGO:00082839.1PCNA, TP53
2base-excision repairGO:00062849.0PCNA, TP53
3nucleotide-excision repairGO:00062898.8PCNA, TP53

Molecular functions related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1receptor tyrosine kinase bindingGO:00309719.1PCNA, TP53

Sources for Grade Iii Astrocytoma

About this section
26ICD10 via Orphanet
34MESH via Orphanet
47OMIM via Orphanet
57SNOMED-CT via Orphanet
62UMLS via Orphanet